Topmost Trends in the Ankylosing Spondylitis Market Forecast to 2030 by Types, Applications, Growth Factor

 

Absolute Markets Insights has announced addition of an insightful analytical data to its massive repository titled Ankylosing Spondylitis Market. Global competitors also highlighted in the study in order to get a stronger and effective outlook of the competition at domestic as well as global regions. In addition, the report also provides comprehensive information based on primary and secondary research methods for accurate data exploration.

Competitive Outlook: AbbVie Inc, Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi Aventis, CELGENE Corporation, Celltrion Healthcare Co., Ltd., Eisai Co., Ltd., Galapagos NV, Protalix Ltd., Regeneron Pharmaceuticals, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, UCB S.A., and Xian Janssen Pharmaceutical Ltd amongst others.

The ankylosing spondylitis market, in terms of revenue, was valued at US$ 5.34 Bn in 2020 and is expected to reach US$ 6.84+ Bn by 2030.Ankylosing Spondylitis (AS) is a common chronic inflammatory rheumatic disease, which are seen in young adults, often in their late teens or early twenties. It can cause pain in lower back and neck. Over the time, AS can cause spine to become curved and rigid and affecting the shape of spine. Normally AS causes pain in spine but in some cases AS can cause swelling and pain in heels, chest, hips and shoulders. Early diagnosis is crucial in ankylosing spondylitis as spinal deformity can be minimized with the help of proper treatment.

Get Full Information of this premium report: https://www.absolutemarketsinsights.com/reports/Ankylosing-Spondylitis-Market-2018-2026-123

Management of ankylosing spondylitis can be done with pharmacological and nonpharmacological treatments. Pharmacological treatments are limited but however researchers are working on innovations in biological drugs and improvements of the treatment in this field. These treatments involve preservation of physical function, control of inflammation and symptoms and stoppage of progressive structural damage and disabilities. In pharmacological treatments, non-steroidal anti-inflammatory drugs (NSAIDs) can help to reduce the symptoms and signs of axial movements with spondyloarthropathies.

In many studies it has been observed that, NSAIDs provide great and rapid relief to inflammatory back pain. However, with this treatment, several rebound symptoms such as stiffness, swelling and joint pain can be observed after few days. Nonpharmacological treatments for ankylosing spondylitis involves regular exercise and patient training. It has been observed that these treatments are helpful in enhancement of spinal mobility parameters however they have not affected disease activity.

Ankylosing Spondylitis Market:

By Drug Type

• Nonsteroidal Anti-Inflammatory Drugs
• TNF blockers
• Immunosuppressive Drugs
• Anti-Inflammatory Drugs
• Steroids
• JAK Inhibitors
• Others (IL-17 Inhibitors)

By Application

• Juveniles
• Adults

By Region:

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

Contact Us:

Company: Absolute Markets Insights
Email id: sales@absolutemarketsinsights.com 
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
Website: https://www.absolutemarketsinsights.com/